Knight Cardiovascular Institute, Oregon Health & Science University, UHN-62, 3181 SW Sam Jackson Park Rd, Portland, OR, 97239, USA,
J Nucl Cardiol. 2013 Dec;20(6):990-1001. doi: 10.1007/s12350-013-9785-0.
Techniques for in vivo assessment of disease-related molecular changes are being developed for all forms of non-invasive cardiovascular imaging. The ability to evaluate tissue molecular or cellular phenotype in patients has the potential to not only improve diagnostic capabilities but to enhance clinical care either by detecting disease at an earlier stage when it is more amenable to therapy, or by guiding most appropriate therapies. These new techniques also can be used in research programs in order to characterize pathophysiology and as a surrogate endpoint for therapeutic efficacy. The most common approach for molecular imaging involves the creation of novel-targeted contrast agents that are designed so that their kinetic properties are different in disease tissues. The main focus of this review is not to describe all the different molecular imaging approaches that have been developed, but rather to describe the status of the field and highlight some of the clinical and research applications that molecular imaging will likely provide meaningful benefit. Specific target areas include assessment of atherosclerotic disease, tissue ischemia, and ventricular and vascular remodeling.
正在为所有形式的无创性心血管成像开发用于评估疾病相关分子变化的体内技术。评估患者组织分子或细胞表型的能力不仅有可能提高诊断能力，而且还可以通过在疾病更易于治疗的早期阶段进行检测，或者通过指导最合适的治疗方法来增强临床护理。这些新技术还可以用于研究计划中，以描述病理生理学并作为治疗效果的替代终点。分子成像最常见的方法是创建设计为使它们在疾病组织中的动力学特性不同的新型靶向对比剂。本综述的主要重点不是描述已经开发的所有不同的分子成像方法，而是描述该领域的现状并突出一些分子成像可能提供有意义的益处的临床和研究应用。具体的目标领域包括评估动脉粥样硬化疾病、组织缺血和心室及血管重塑。
